CEL-SCI CORP Files DEFA14A Proxy Materials

TL;DR

CVM filed proxy docs, shareholders need to pay attention to upcoming votes.

AI Summary

CEL-SCI CORPORATION (CVM) has filed a Definitive Additional Materials proxy statement (DEFA14A) on March 7, 2024. This filing relates to materials provided to shareholders regarding company matters. The company, previously known as INTERLEUKIN 2 INC, is incorporated in Colorado and headquartered in Vienna, VA.

Why It Matters

This filing indicates that CEL-SCI CORPORATION is providing important information to its shareholders, likely concerning upcoming votes or corporate decisions that could impact the company's direction and stock value.

Risk Assessment

Risk Level: low — This is a routine proxy filing and does not inherently indicate new risks, but the underlying company operations carry their own risks.

Key Players & Entities

• CEL-SCI CORPORATION (company) — Registrant
• CVM (company) — Ticker Symbol
• INTERLEUKIN 2 INC (company) — Former Company Name
• 8229 BOONE BLVD . SUITE 802 VIENNA, VA 22182 (company) — Business Address

FAQ

Key Financial Figures

• $2 billion — turing plant that can make an estimated $2 billion worth of Multikine annually. CEL-SCI i

Filing Documents

• cvm_def14a.htm (DEFA14A) — 41KB
• cvm_def14aimg1.jpg (GRAPHIC) — 4KB
• 0001654954-24-002764.txt ( ) — 47KB

Forward-Looking Statements

Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the terms, expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2023. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. * Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. 4

View Full Filing

View this DEFA14A filing on SEC EDGAR